TECHNOLOGY CONNEXIN43 – NOVEL TARGET

“I started with basic research, and through the years we gained quite an understanding of the underlying mechanisms of connexin channels. We wanted to use the knowledge we gained to help patients through the development of therapeutics.”

- Dr. Jean Jiang

Our innovative therapeutics are based upon the novel findings of multiple functions of connexin 43 channels on CNS diseases and cancers. These antibodies affect the function of connexin43 hemichannels in osteocytes and astrocytes and produce significant therapeutic results.

We are currently in clinical trials on two programs, one for acute spinal cord injury (ALMB-0166) and the other for bone-involved cancers (ALMB-0168), and have several other therapeutic targets in the development pipeline.

Learn More:

RELEVANT PUBLICATIONS

b Zhou, J. Z., Riquelme, M. A., Gao, X., Ellies, L. G., Sun, L. Z., & Jiang, J. X. (2015). Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene, 34(14), 1831–1842. Read Article.

b Zhou, J. Z., Riquelme, M. A., Gu, S., Kar, R., Gao, X., Sun, L., & Jiang, J. X. (2016). Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis. Oncogene, 35(43), 5597–5607. Read Article.